, , p.675
Cloning, functional expression, and chromosomal localization of the human 676 pancreatic islet glucose-dependent insulinotropic polypeptide receptor, Diabetes, vol.44, pp.1202-677, 1995. ,
,
Overlap of endocrine 680 hormone expression in the mouse intestine revealed by transcriptional profiling and flow 681 cytometry, Endocrinology, vol.153, pp.3054-65, 2012. ,
,
Sclerostin antibody 684 treatment improves bone mass, bone strength, and bone defect regeneration in rats with 685 type 2 diabetes mellitus, J Bone Miner Res, vol.28, pp.627-665, 2013. ,
GLP-1 and 687 calcitonin concentration in humans: lack of evidence of calcitonin release from sequential 688 screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated 689 with the human GLP-1 analog, liraglutide, J Clin Endocrinol Metab, vol.96, pp.853-60, 2011. ,
Glucagon-like peptide-1 mediates the therapeutic actions 691 of DPP-IV inhibitors, Diabetologia, vol.48, pp.612-617, 2005. ,
,
Bone loss accompanying voluntary 703 weight loss in obese humans, J Bone Miner Res, vol.9, pp.459-63, 1994. ,
GLP-1 agonists for type 2 diabetes: 705 pharmacokinetic and toxicological considerations, Expert Opin Drug Metab Toxicol, vol.9, pp.17-29, 2013. ,
,
Attenuation by incretins of thyroid 708 hormone-stimulated osteocalcin synthesis in osteoblasts, Biomed Rep, vol.5, pp.771-775, 2016. ,
Collagen advanced 710 glycation inhibits its Discoidin Domain Receptor 2 (DDR2)-mediated induction of lysyl 711 oxidase in osteoblasts, Bone, vol.58, pp.33-41, 2014. ,
,
Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially 714 through the down-regulation of SOST/sclerostin in osteocytes, Life Sci, vol.92, pp.533-573, 2013. ,
,
Bone loss and bone turnover in diabetes, Diabetes, vol.44, pp.775-82, 1995. ,
,
Impaired insulin signaling in 719 endothelial cells reduces insulin-induced glucose uptake by skeletal muscle, Cell Metab, vol.13, pp.294-307, 2011. ,
,
Effect of Glucagon-729 like Peptide-1 on the Differentiation of Adipose-derived Stem Cells into Osteoblasts, p.730, 2015. ,
, Adipocytes. J Menopausal Med, vol.21, pp.93-103
,
Endocrine regulation of energy 733 metabolism by the skeleton, Cell, vol.130, pp.456-69, 2007. ,
Effect of 735 exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed 736 type 2 diabetes, Acta Diabetol, vol.52, pp.1083-91, 2015. ,
The influence of diabetes mellitus on the healing of closed fractures, Clin, vol.738, 1988. ,
, Orthop Relat Res, pp.210-216
, , 2015.
, Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in 741 ovariectomized rats without diabetes, PLoS One, vol.10, p.132744
,
Basal and stimulated calcitonin levels in patients with type 2 diabetes 744 did not change during 1 year of Liraglutide treatment, Metabolism, vol.65, pp.1-6, 2016. ,
Exendin-746 4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone 747 formation and suppressing bone resorption in aged ovariectomized rats, J Bone Miner Res, vol.748, pp.1641-52, 2013. ,
Optimal 755 bone mechanical and material properties require a functional glucagon-like peptide-1 756 receptor, J Endocrinol, vol.219, pp.59-68, 2013. ,
High fat-fed 758 diabetic mice present with profound alterations of the osteocyte network, Bone, vol.90, pp.99-106, 2016. ,
,
Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality 761 in Type 1 Diabetes Mellitus, J Cell Physiol, vol.230, pp.3009-3027, 2015. ,
Pleiotropic actions of the incretin 763 hormones, Vitam Horm, vol.84, pp.21-79, 2010. ,
Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic 766 Differentiation through beta-Catenin, Stem Cell Reports, vol.6, p.633, 2016. ,
Glucose-768 dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone 769 strength and quality, Bone, vol.56, pp.337-379, 2013. ,
,
Double incretin receptor knock-out (DIRKO) mice 772 present with alterations of trabecular and cortical micromorphology and bone strength, 2015. ,
The Activity of Adiponectin in Bone, 2017. ,
, Tissue Int, vol.100, pp.486-499
, , p.785
Mechanisms of diabetes mellitus-786 induced bone fragility, Nat Rev Endocrinol, 2016. ,
,
GLP-1 and exendin-4 can reverse 789 hyperlipidic-related osteopenia, J Endocrinol, vol.209, pp.203-213, 2011. ,
,
Exendin-4 exerts osteogenic actions in insulin-792 resistant and type 2 diabetic states, Regul Pept, vol.159, pp.61-67, 2010. ,
,
, , 2010.
, Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-796 linked GLP-1 receptor, J Cell Physiol, vol.225, pp.585-92
,
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes 799 patients with stable coronary artery disease, Am J Physiol Endocrinol Metab, vol.287, pp.1209-1224, 2004. ,
,
Two doses of sclerostin antibody in 802 cynomolgus monkeys increases bone formation, bone mineral density, and bone strength, 2010. ,
Increased cortical porosity in type 2 diabetic postmenopausal women with, 2013. ,
Role of collagen enzymatic and glycation 837 induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob 838 rats, Osteoporos Int, vol.17, pp.1514-1537, 2006. ,
,
Pentosidine and increased fracture risk in older adults with type 2 diabetes, J Clin, vol.842, 2009. ,
, Endocrinol Metab, vol.94, pp.2380-2386
,
Older women 845 with diabetes have a higher risk of falls: a prospective study, Diabetes Care, vol.25, pp.1749-54, 2002. ,
,
, , 2011.
, Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes
, JAMA, vol.305, pp.2184-92
, , p.851
, , 2008.
, Diabetes-related complications, glycemic control, and falls in older adults, Diabetes Care, vol.31, pp.391-397
,
Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 856 1 and Type 2 Diabetes, Diabetes, vol.65, pp.1757-66, 2016. ,
Bone structure and turnover in type 2 diabetes mellitus, Osteoporos Int, vol.23, pp.635-676, 2012. ,
,
GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion, 2015. ,
Risk of bone fractures associated with glucagon-like peptide-1 receptor 865 agonists' treatment: a meta-analysis of randomized controlled trials, Endocrine, vol.48, pp.107-122, 2015. ,
,
Effect of dipeptidyl peptidase-4 inhibition 868 on circadian blood pressure during the development of salt-dependent hypertension in rats, 2015. ,
, , 2017.
, Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway. PLoS One, 892 like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats, Cardiovasc Diabetol, vol.918, p.29